Press release 2012-03-05
FDA approval of the C-RAD Catalyst system
C-RAD AB with its four fully owned subsidiaries are all active in the field of radiation therapy. C-RAD has received FDA approval for its Catalyst system with unique capabilities for use in advanced radiation therapy. Sales to the important US market have been started.
The Catalyst system is based on a new generation of hardware and software platform for high performance optical surface scanning and augmented reality through re projection. Advanced and highly optimized algorithms for non-rigid registration and deformable models enable the real-time assessment of patient positioning errors before and during treatment delivery. The system is calculating iso center adjustments. Interfaces to major LINAC vendors ensure a completely integrated workflow.
Catalyst has been approved by Food and Drug Administration to be used for positioning, motion control and respiratory gating. Communication with the Varian MMI interface for auto set up and respiratory gating has also been approved.
Erik Hedlund, CEO of C-RAD AB:
“In October 2011 the Catalyst system was released for sales in the European market. Sales immediately increased. With the FDA approval about two thirds of the world market in radiation therapy can be approached. The second Catalyst system in the US was last week installed at McLaren Institute in Lapeer, Michigan.
Both the FDA approval and approval of the communication with the Varian MMI interface will have a major impact on C-RAD sales. ”
For further information:
Erik Hedlund, CEO C-RAD AB, Phone +46 (0)18 66 69 31, E-mail erik.hedlund@c-rad.se
